Veloxis Pharmaceuticals, an Ashai Kasei company, today announced dosing of the first patient by its partner, Xenikos, in a global pivotal Phase 3...
Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, today announced that the first participant has been dosed in a Phase 1 Study of VEL-101...
NANTES, France, Feb. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has obtained fast track designation from the U.S. Food & Drug Administration (FDA) for VEL-101/FR104, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in recipients of kidney transplants. Fast track designation is granted by the FDA to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need.
NANTES, France and CARY, N.C., April 26, 2021 /PRNewswire/ -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Veloxis Pharmaceuticals Inc., a subsidiary of Asahi Kasei, today announced a global license agreement granting Veloxis Pharmaceuticals worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. In parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases. Through this license agreement, Veloxis plans to develop FR104 to provide a new therapeutic option for prophylaxis of organ rejection in patients receiving a solid organ transplant.
Athena Licenses Veloxis’ Lipid-Lowering Drug AtorFen for Emerging Markets